Skip to main content
Home

oAv Menu

  • Home
  • Patient Care Center
  • Clinical Trials
  • Providers
    • Therapeutics
    • People
    • Places
  • Community Center
    • Community Stories
    • Social Media
    • Community Content
    • Financial Assistance
  • News
    • Community Events
    • Clinical Trials and Research
    • Business
    • News People
    • Happenings
    • Spotlight
    • Fundraising Events
  • Trusted Resources
    • Education
    • Videos & Visuals
  • Event Calendar
  • Login
  • Search
Change point analysis of the total PYP orders showed a significant difference in the number of PYP orders
Increasing clinicians’ suspicion of ATTR amyloidosis using a retrospective algorithm
Jan 15, 2026

News

New Guidelines Aim to Improve AL Amyloidosis Diagnosis
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Feb 02, 2026
Nuclear imaging in transthyretin amyloid cardiomyopathy
Nuclear imaging in transthyretin amyloid cardiomyopathy
Feb 02, 2026
FDA lifts clinical hold on Phase 3 trial of nex-z for hATTR-PN
FDA lifts clinical hold on Phase 3 trial of nex-z for hATTR-PN
Feb 02, 2026
Raising Awareness for Rare Diseases: Spotlight on Amyloidosis
Raising Awareness for Rare Diseases: Spotlight on Amyloidosis
Feb 01, 2026
Nerve damage often goes unrecognized in adults with hATTR-CM
Nerve damage often goes unrecognized in adults with hATTR-CM
Jan 29, 2026
More in News

Education

ashpublications
Clinical Features of Systemic Amyloidosis: A Scoping Review
Jan 27, 2026
 Etiologic Confirmation
AL Cardiac Amyloidosis Presenting as Grade 3 ATTR Mimicry on Scintigraphy
Jan 23, 2026
CRISPR-Cas3
https://www.oreateai.com/blog/understanding-hattr-a-deep-dive-into-hereditary-transthyretin-amyloidosis/23903414f6a0a602d9aca557d23f138c
Jan 21, 2026
Multimodal Cardiac Imaging
AL Cardiac Amyloidosis Presenting as Grade 3 ATTR Mimicry on Scintigraphy
Jan 21, 2026
 transthyretin cardiac amyloidosis (ATTR-CM)
How to Manage Nerve Damage if You Have ATTR-CM
Jan 20, 2026
More in Education

Community Center

My name is Faye.
My Journey with Amyloidosis: Turning Fear into Purpose
Feb 15, 2026
ATTR amyloidosis
The “Mixed Phenotype” Mystery: Why Your hATTR Diagnosis Might Only Be Half the Story
Jan 28, 2026
My Amyloid Story Begins
My Amyloid Story Christine Giosa
Jan 15, 2026
Gurmit’s Story
A Second Chance at Life: Gurmit’s Story
Jan 13, 2026
A Legacy of Hope: Alison’s Story
A Legacy of Hope: Alison’s Story
Jul 29, 2025
More in Community Center

Hot Topics

Healthy Meal Planning
Healthy Meal Planning: Tips for Older Adults
Mar 12, 2025
An Elderly Mother and an Aging Son
An Elderly Mother and an Aging Son: A Journalist’s Caregiving Story
Mar 07, 2025
Patient Safety and Quality: An Evidence-Based Handbook for Nurses
Supporting Family Caregivers in Providing Care
Mar 04, 2025
Caregiver Responsibilities
Live-In Caregivers for Elderly
Feb 26, 2025
Hidden Cost of Caregiving
The Hidden Cost of Caregiving: Stress, Anxiety, and Coping Mechanisms
Jan 23, 2025

Video

Newsletter

Stay informed - subscribe to our newsletter.
The subscriber's email address.

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion

Featured Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis

Footer menu

  • Home
  • About us
  • Video
  • Galleries
  • Contact
  • Login
  • Privacy Policy
  • Privacy Reminder
  • Terms of use
  • FAQ
  • Code of Conduct

© 2025 Somebody To Talk To, Inc.

Join us on                     
Alnylam Logo external link, opens in a new tabPfizer Logo external link, opens in a new tabBridgebio Logo external link, opens in a new tabAttralus Logo external link, opens in a new tabProthena Logo external link, opens in a new tab
Amyloidosis Foundation Logo external link, opens in a new tab